NNZ-2566 is a drug that intends to reduce brain inflammation. Much of its development has been funded by the military since it is hoped that this drug could reduce the effects of brain trauma. Now the Neuren Corporation is planning clinical trials with children with Rett syndrome and is currently developing the protocol for the trials. Continue reading
Search this Blog Site
Visit the 401 Project or Donate.. Click image below.
MECP2 Duplication Syndrome Fund
MECP2 Family Talk Facebook Group
FOLLOW THIS BLOGYou can follow this blog on Twitter, RSS Feeds, or Networked Blogs using the buttons below:
Follow on Twitter